 |
|
Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
Douglas J. Watson, PhD;
Sean E. Harper, MD;
Peng-Liang Zhao, PhD;
Hui Quan, PhD;
James A. Bolognese, MStat;
Thomas J. Simon, MD
Arch Intern Med. 2000;160:2998-3003.
Background Most nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective cyclooxygenase (COX-1 and COX-2) inhibitors and are associated with a variety of upper gastrointestinal (GI) tract symptoms. The roles of COX-1 and COX-2 in the pathogenesis of these symptoms are unclear. To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs.
Methods A prespecified, combined analysis of investigator-reported GI AEs in all 8 double-blind, randomized, phase 2b/3 osteoarthritis trials of rofecoxib was conducted. Patients included men and women with osteoarthritis (N = 5435); there was no upper age limit for entry. Treatments tested included rofecoxib, 12.5, 25, or 50 mg (combined), vs ibuprofen, diclofenac, or nabumetone (combined). Primary outcomes were the time (by survival analysis) to (1) treatment discontinuation due to GI AEs and (2) first reported dyspeptic-type GI AE. Between-treatment comparisons were made by log-rank test.
Results The number of treatment discontinuations caused by GI AEs during 12 months was significantly lower (P= .02) with rofecoxib vs NSAIDs (8.2 vs 12.0 per 100 patient-years; relative risk, 0.70; 95% confidence interval, 0.52-0.94). The incidence of prespecified dyspeptic-type GI AEs during the first 6 months was significantly lower (P= .02) with rofecoxib vs NSAIDs (69.3 vs 85.2 per 100 patient-years; relative risk, 0.85; 95% confidence interval, 0.74-0.97). However, the difference between treatments in dyspeptic-type GI AEs was attenuated after 6 months.
Conclusion Rofecoxib was associated with a lower incidence of treatment discontinuations due to GI AEs over 12 months and a lower incidence of dyspeptic-type GI AEs over 6 months than treatment with nonselective COX inhibitors, or NSAIDs.
From Merck Research Laboratories, West Point, Pa.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks
SPINK et al.
Journal of the American Dental Association 2005;136:1439-1448.
ABSTRACT
| FULL TEXT
Taking stock of coxibs
DTB 2005;43:1-6.
ABSTRACT
| FULL TEXT
Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee: A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Roth and Shainhouse
Arch Intern Med 2004;164:2017-2023.
ABSTRACT
| FULL TEXT
Three-Tiered-Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs
Briesacher et al.
Arch Intern Med 2004;164:1679-1684.
ABSTRACT
| FULL TEXT
Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis: A Randomized, Controlled Trial
Lisse et al.
ANN INTERN MED 2003;139:539-546.
ABSTRACT
| FULL TEXT
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs
MacDonald et al.
Gut 2003;52:1265-1270.
ABSTRACT
| FULL TEXT
The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis
Spiegel et al.
ANN INTERN MED 2003;138:795-806.
ABSTRACT
| FULL TEXT
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data
Layton et al.
Rheumatology (Oxford) 2003;42:622-631.
ABSTRACT
| FULL TEXT
Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen
Bensen et al.
Rheumatology (Oxford) 2002;41:1008-1016.
ABSTRACT
| FULL TEXT
Safety of a Cyclooxygenase-2 Inhibitor in Patients With Aspirin-Sensitive Asthma*
Martin-Garcia et al.
Chest 2002;121:1812-1817.
ABSTRACT
| FULL TEXT
Management of knee osteoarthritis
LEEB and JAWAD
Ann Rheum Dis 2001;60:984-984.
FULL TEXT
Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
Mukherjee et al.
JAMA 2001;286:954-959.
ABSTRACT
| FULL TEXT
|
